Toward a Society Where Everyone Is Watched Over by a Personal AI Doctor, 24 Hours a Day. Is It Time to License AI Doctors?

Proposing the “Clinical AI License,” a new system enabling independent initial diagnosis and prescribing. A Perspective article by Yusaku Fujii, Professor at Gunma University, “Toward a Clinical AI License for Independent Initial Diagnosis and Prescribing in Primary Care,” has been published in the international journal AI (MDPI).

Aiming at a society in which everyone is watched over by a personal AI doctor 24 hours a day, the  article proposes the “Clinical AI License,” a new licensing system that permits AI to perform initial  diagnosis and prescribing independently. Rather than waiting for the arrival of AGI (artificial general 

intelligence), the concept is to authorize AI step by step, starting from clinical domains in which  sufficient capability and safety have been confirmed, and to widen the scope from there. 

The article discusses why this system should be considered now and what social value can be  expected, and sets out four requirements (performance standards, staged clinical evaluation,  expansion of clinical scope, and continuous monitoring) together with the legal responsibility of the  operating entity. 

Key Points 

• A call to license AI doctors: From AI that assists physicians to AI that independently performs  initial diagnosis and prescribing within a certified scope. A proposal to move the healthcare system  one step forward. 

• Start without waiting for AGI: There is no need to wait for an all-capable AI doctor. Authorization  begins with diseases and clinical acts that have been sufficiently evaluated. 

• Four concrete licensing requirements: Domain-specific performance standards, staged evaluation  modeled on clinical trials, expansion of the authorized scope, and continuous monitoring are  combined. 

• Clear responsibility: The license is granted to the entity that operates a certified AI under the  certified conditions, and that entity bears the legal responsibility. 

• Changing the shape of healthcare: The article shows a path toward continuous 24-hour  consultation and support, smaller regional disparities, a response to physician shortages, and  containment of healthcare costs. 

The Society We Aim For: A Personal AI Doctor, 24 Hours a Day 

• Care you can consult at any time: An environment in which patients can ask about symptoms and  health concerns whenever they need to, including late at night and on holidays. 

• Continuous understanding of each person: Medical history, medication, living conditions, and  changes in health status are followed continuously, leading to advice and initial care suited to the  individual. 

• Diagnosis and prescribing in authorized domains: In clinical domains that AI has been evaluated  as able to handle, the aim is to provide initial diagnosis, prescribing, and follow-up as one integrated  service. 

• Human physicians when needed: Urgent symptoms and cases outside the authorized scope are  handed over promptly to human physicians and medical institutions.

Is It Time to License AI Doctors? 

Recent medical LLMs have shown strong results on limited diagnostic tasks and in studies of initial  management, and their application to prescribing support and medical safety is advancing. The  current system, however, is structured so that clinical authority for diagnosis and prescribing is given,  in principle, to qualified humans. 

The issue is not to keep debating in the abstract whether AI has medical competence. It is to build a  system that defines in which clinical domains, and at what demonstrated level of performance and  safety, how much may be entrusted to AI. 

• No need to be all-capable from the start: Introduction is considered first in domains that can be  evaluated safely, such as common diseases and some stable chronic conditions. 

• Built on existing medical device approval: In light of progress in SaMD (Software as a Medical  Device) with autonomous functions, a system addressing the authority and responsibility for  independent clinical acts is added. 

The Four Requirements of the Clinical AI License 

• (1) Performance standards for each clinical domain: Evaluation covers not only diagnostic  accuracy but also appropriateness of prescribing, handling of contraindications, prevention of  missed emergency patients, and handover to human physicians. 

• (2) Staged evaluation modeled on clinical trials: Independent clinical practice is permitted after  confirmation of safety and performance, multi-site comparative evaluation, and large-scale  evaluation in real clinical settings. 

• (3) Stepwise expansion of clinical scope: Practice begins with certified diseases and prescriptions  and, based on the track record, is extended to individually approved domains. 

• (4) Continuous monitoring and suspension: Performance and adverse events are monitored after  introduction; if performance falls below the standard, independent practice is suspended and care is  handed over to human physicians. 

No Ambiguity About the Responsibility of AI Doctors 

• The license is granted to the operating entity: Not the AI itself but the entity that operates the  certified AI under the certified conditions becomes the license holder and bears primary  responsibility for the clinical acts.

• Verifiable clinical records: Patient input, the medical knowledge referenced, the basis of the  output, and the resulting decision are recorded, so that the process of diagnosis and prescribing can  be verified afterward. 

• Institutionalized safety and accountability: Cross-checking by multiple models, auditable records  based on VRAIO, and confirmation by human physicians in the early phase of introduction are  combined. 

• Secured compensation for patients: Liability insurance is required of the operating entity, so that  relief for patients does not depend solely on the entity’s own financial resources. 

How Access to Care and Health Economics Would Change 

• Narrowing regional disparities: Even in regions short of physicians, standardized initial care could  become accessible remotely. 

• Medical professionals where they are needed: If AI takes on routine initial care, human physicians  can concentrate on complex diseases, exceptional cases, and advanced specialist judgment. 

• Changing the cost of delivering care: Diagnostic capability can be extended to many regions and  users, which could ease the burden on healthcare spending and health insurance finances. 

• The smartphone as the entrance to care: The concept combines dialogue with the patient, images  and audio, home measurement devices, and medication delivery to bring initial care into everyday  life. 

This Publication and Next Steps 

The published article is a Perspective that presents the social significance of independent initial diagnosis and prescribing by AI and the institutional requirements for authorizing it. The tasks ahead are staged evaluation on a narrowed set of target diseases, verification of effectiveness and safety in  real clinical practice, and concrete design of the legal and liability framework. 

Not a binary choice of whether or not to allow AI doctors, but a question of what to entrust, under  which conditions, and in what order. This work calls for discussion to advance AI medicine as a social  institution. 

Publication and Funding 

Y. Fujii, “Toward a Clinical AI License for Independent Initial Diagnosis and Prescribing in Primary  Care,” AI (MDPI), Vol.7, No.11, 480, 2026.  

https://www.mdpi.com/2673-2688/7/11/480

Funding: JSPS KAKENHI 26K21972 (as stated in the Funding section of the article)

Related Key Publications 

[1] Y. Fujii, “No Trust Without Trust Infrastructure: The Extended Kelvin Principle and Its Application  to AI Output Governance,” AI, vol. 7, no. 6, art. no. 218, 2026. https://doi.org/10.3390/ai7060218 

[2] Y. Fujii, “VRAIO as a Safety Valve: Governing AI Platform Outputs at Societal Scale,” AI and Ethics,  vol. 6, art. no. 340, 2026. https://doi.org/10.1007/s43681-026-01206-z 

[3] Y. Fujii, “From Measurement Failure to Privacy Infrastructure: Reframing Contact Tracing  Governance for the Next Pandemic,” Journal of Medical Internet Research, vol. 28, e99645, 2026.  https://doi.org/10.2196/99645 

Contact 

Yusaku Fujii, Professor 

Graduate School of Science and Technology, Gunma University E-mail: [email protected]

Research profile: http://www.e-jikei.org/fujii/fujii.htm 

For interviews, please contact the author directly by e-mail. Requests for contributed articles on this  proposal are also welcome. 

This press release is issued by Yusaku Fujii in his individual capacity as a researcher.

 


Advertisement

Published: 17 Nov 2026

Country: 
Journal:
AI
Academic discipline: 
Content type: 
Reference: 

Y. Fujii, “Toward a Clinical AI License for Independent Initial Diagnosis and Prescribing in Primary Care,” AI (MDPI), Vol.7, No.11, 480, 2026.
https://www.mdpi.com/2673-2688/7/11/480

Funding information:

Japan Society for the Promotion of Science
JSPS KAKENHI 26K21972